KAKKIS EMIL D (President & CEO) sold 0.9% of their position (20K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $1.00M — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/7/2024ACC: 0000950170-24-092608
DirectorOfficer· President & CEO
Since Mar 2026
-20K
Net shares
Net seller
$1.00M
Total sold
1
Open market trades
0B · 1S
1
Total transactions
20K disposed
Non-Derivative Transactions1
Common Stock
Indirect
Shares
−20K
Price / share
$50.17
Trade value
$1M
% of position
0.9%
8/6/2024
2.26M→2.24M
Total
Net shares
−20K
Net value
-$1M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/6/2024 | S · Sale | −20K | $50.17 | $1M | 0.9% | 2.26M | 2.24M |
| Total | −20K | -$1M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned564.60K
Total
564.60K direct564.60K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 564.60K | Direct |
| Total | 564.60K | 564.60K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported